COMBOGESIC Now Available Through Mark Cuban Cost Plus Marketplace

DALLAS and AUCKLAND, New Zealand, Oct. 29, 2026 /CourierPR/ -- AFT Pharmaceuticals has expanded access to its prescription non-opioid pain medication, COMBOGESIC® (acetaminophen 325 mg/ibuprofen 97.5 mg) tablets, by making them available through the Mark Cuban Cost Plus Marketplace. This move marks a significant step in the company's mission to improve access to non-opioid pain treatments in the United States.

COMBOGESIC is a fixed-dose combination of two well-established pain relievers, designed for the short-term management of mild to moderate acute pain. Under its FDA-approved dosing regimen, patients may take three tablets every six hours as needed, up to a maximum of 12 tablets in 24 hours. This regimen provides a maximum daily dose of 3,900 mg acetaminophen and 1,170 mg ibuprofen. The launch of COMBOGESIC through the Mark Cuban Cost Plus Marketplace is aimed at providing pharmacies, hospitals, clinics, and other eligible healthcare organizations with an additional channel to source this prescription non-opioid treatment.

The 2022 CDC Clinical Practice Guideline found that non-opioid therapies are at least as effective as opioids for many common types of acute pain and recommends the use of non-opioid options. COMBOGESIC gives hospitals, surgery centers, and clinics a prescription-strength, non-opioid option to support this approach. Healthcare organizations can now order COMBOGESIC with just a few clicks on their Mark Cuban Cost Plus Marketplace account, providing patients with a clinically studied regimen prescribed and supervised by their clinician, rather than working out a schedule for two separate products.

In a Phase 3 study of 408 adults with moderate-to-severe pain following dental surgery, only 23.9% of patients receiving COMBOGESIC required opioid rescue medication, compared with 43.2% on ibuprofen alone and 53.2% on acetaminophen alone. COMBOGESIC also provided 78% more effective pain relief than acetaminophen alone and 36% more than ibuprofen alone (both P<0.001), with tolerability comparable to either component. These findings underscore the effectiveness and safety of COMBOGESIC in managing acute pain.

AFT Pharmaceuticals, a growing New Zealand-based multinational pharmaceutical company, has a broad portfolio of pharmaceutical products across a wide range of therapeutic categories. COMBOGESIC is backed by extensive clinical evidence and is already available in 67 countries worldwide. It is now available through the Mark Cuban Cost Plus Marketplace, further expanding its reach and accessibility in the United States.

For more information, visit Combogesic.com or Access Combogesic. The company's website, AFT Pharmaceuticals US, Inc., provides detailed information on its products and services. COMBOGESIC is contraindicated in patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product. It is also contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.

The company's commitment to improving access to non-opioid prescription pain treatments is reflected in its extensive clinical evidence and global presence. COMBOGESIC is now available to healthcare organizations through the Mark Cuban Cost Plus Marketplace, providing a safe, effective, and non-opioid option for managing acute pain.